Acellular pertussis vaccine based on outer membrane vesicles capable of conferring both long-lasting immunity and protection against different strain genotypes

GAILLARD MARÍA EMILIA; BOTTERO DANIELA; ERREA AGUSTINA; ORMAZABAL MAXIMILIANO; ZURITA MARÍA EUGENIA; MORENO GRISELDA; RUMBO MARTÍN; VAN DER LEY PETER; VAN DER ARK ARNO; HOZBOR DANIELA

Dublin

Simposio; 10th International Symposium on Bordetella; 2013

Trinity Biomedical Sciencies Institute

Despite high vaccination coverage rates, pertussis continues to be a global concern, with increased incidence widely noted. The current pertussis epidemiologic situation has been mainly attributed to waning immunity and pathogen adaptation. To improve the pertussis disease control it seems to be necessary a new generation of vaccines capable of conferring both long-lasting immunity and protection against different Bordetella genotypes. Previously, we have demonstrated that the outer membrane vesicles (OMVs) obtained from B. pertussis are good vaccine candidates to protect against pertussis. Moreover, OMVs obtained from recombinant B. pertussis strain expressing PagL enzyme constitute a safer formulation (OMVsBpPagL), without altering protective immunity. In this work the OMVsBpPagL formulated with diphtheria and tetanus toxoids (TdapOMVsBpPagL) were used in an established murine immunization model to examine the induction and longevity of immunological memory and protection against different B. pertussis bacterial background..